ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Ly firstwordpharma
August 27, 2021Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi? (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy. -
EMA human medicines committee meeting highlights, June 2021 europeanpharmaceuticalreview
June 28, 2021Drugs recommended for approval by the European Medicines Agency’s human medicines committee included a gene therapy and two generics, among five others.
Pharma Sources Insight January 2025
